Centessa Pharmaceuticals Plc

  • Safety Score
  • Market Cap $1.97B
  • PE -12
  • Debt $75.70M
  • Cash $395.03M
  • EV $1.65B
  • FCF -$130.37M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$161.27M
EBIT-$157.81M
ROE-32%
ROA-26%
FCF-$130.37M
Equity$499.14M
Growth Stability1
PE-12.2
PB3.94
P/FCF-15.1
Price/Cash0.2
Debt/Equity0.15
Debt/FCF-0.58
Equity CAGR-14%
Earnings Growth YoY10%
Earnings Growth QoQ-3%
Equity CAGR 5Y-14%
Equity CAGR 3Y-16%
Market Cap$1.97B
Assets$609.72M
Total Debt$75.70M
Cash$395.03M
Shares Outstanding108.2M
EV1.65B
Safety Score65%
Working Capital541.96M
Current Ratio21.52
Shares Growth 3y9%
Equity Growth QoQ74%
Equity Growth YoY92%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others.

SEC Filings

Direct access to Centessa Pharmaceuticals Plc (CNTA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Centessa Pharmaceuticals Plc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Centessa Pharmaceuticals Plc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Centessa Pharmaceuticals Plc Discounted Cash Flow

Fully customizable DCF calculator online for Centessa Pharmaceuticals Plc.

= -$1.3B
012345678910TV
fcf-$130M-$130M-$130M-$130M-$130M-$130M-$130M-$130M-$130M-$130M-$130M-$1.3B
DCF-$119M-$108M-$98M-$89M-$81M-$74M-$67M-$61M-$55M-$50M-$503M
Value-$1.3B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201912/202012/202112/202212/2023TTM
Net Margins-----2K%-
ROA--89%-59%-48%-48%-26%
ROE-48%-78%-64%-64%-32%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201912/202012/202112/202212/2023TTM
Debt over FCF--0.53-0.56-0.35-0.47-0.58
Debt over Equity--0.250.150.210.320.15
Growth Stability-----1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth------
Earnings YoY growth-111%3K%-43%-30%-
Equity YoY growth-89%-2K%-32%-30%-14%
FCF YoY growth-82%1K%49%-20%-